EGFR and partial androgen insensitivity syndrome: They hypothesized that owing to the clonal heterogeneity of the tumor and the potential contribution of PDGFRA and EGFR signaling pathways, imatinib did not provide disease control and concluded that the therapeutic activity of this targeted agent in PAIS cannot be determined based on their findings [3].